1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate
ETV6::RUNX1-positive leukemia cells in preclinical models.
(
- Contribution to journal › Article
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
- 2021
-
Mark
Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
(
- Contribution to journal › Article
- 2020
-
Mark
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
(
- Contribution to journal › Article
- 2018
-
Mark
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
(
- Contribution to journal › Article
- 2017
-
Mark
Distinct global binding patterns of the Wilms' tumor gene 1 (WT1) -KTS and +KTS isoforms in leukemic cells
(
- Contribution to journal › Article
- 2016
-
Mark
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
(
- Contribution to journal › Article
- 2015
-
Mark
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
(
- Contribution to journal › Article
-
Mark
The DEK oncoprotein is upregulated by multiple leukemia-associated fusion genes.
(
- Contribution to journal › Letter
- 2014
-
Mark
Molecular Mechanisms of the DEK Protein in Leukemia
(
- Thesis › Doctoral thesis (compilation)